Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokerages […]